Lung Cancer

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery.

Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery, without sacrificing quality of care.

The FDA has approved selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Adding the PD-1 inhibitor sintilimab injection to gemcitabine and platinum-based chemotherapy improved progression-free survival as a frontline treatment in squamous non–small cell lung cancer.

The FDA has approved capmatinib for the treatment of patients with non–small cell lung cancer.

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Edward B. Garon, MD, MS, discusses the importance of the GEOMETRY mono-1 study in patients with advanced NSCLC who harbor MET exon 14 skipping mutations.

The past 2 decades have been transformative for the treatment of non–small cell lung cancer; two-thirds of patients have been found to harbor molecular drivers, and a growing proportion of these are now targetable with FDA-approved drugs.